CXCL12 rs18011157 polymorphism in patients with non-Hodgkin's lymphoma: Is it associated with poor outcome?

Basit Öğe Kaydı
dc.authoridGürkan, Hakan/0000-0002-8967-6124;
dc.authorwosidGürkan, Hakan/AAF-2866-2020
dc.authorwosidUyanik, Mehmet/AAD-7345-2020
dc.contributor.authorPamuk, Gulsum Emel
dc.contributor.authorTozkir, Hilmi
dc.contributor.authorUyanik, Mehmet Sevki
dc.contributor.authorGurkan, Hakan
dc.contributor.authorDuymaz, Julide
dc.contributor.authorPamuk, Omer Nuri
dc.date.accessioned2024-06-12T10:59:01Z
dc.date.available2024-06-12T10:59:01Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: We studied CXCL12-related rs18011157 polymorphism in non-Hodgkin lymphoma (NHL) patients. We also determined the effect of this polymorphism on clinical features and outcome of NHL. Methods: We included 90 NHL patients (54 males, 36 females) and 88 healthy controls (54 males, 34 females). CXCL12-related rs18011157 polymorphism was determined by polymerase chain reaction. Results: rs18011157 polymorphism was significantly more frequent in NHL patients with GA genotype than in healthy controls (37.8% vs. 20.5%, P = 0.011). The frequency of patients with initially high lactate dehydrogenase (LDH) level (65.8% vs. 38.5%) and extranodal involvement (61.1% vs. 43.8%) was significantly higher in the GA plus AA genotype groups when considered altogether (P = 0.01 and 0.09). Poor prognostic factors in univariate analysis were the presence of B symptoms, initially high International Prognostic Index (IPI), splenomegaly, nonresponse to first-line therapy, the presence of early relapse, and carrying A allele (GA plus AA genotypes). The independent prognostic factors in multivariate analysis were only early relapse and an initially high IPI score. Discussion: CXCL12 rs1801157 polymorphism which was found to be associated with extranodal involvement and increased LDH in NHL might be a marker of poor prognosis in patients with GA and AA genotypes. Conclusions: CXCL12-related rs18011517 polymorphism was more frequent in NHL patients: it might be associated with NHL pathogenesis and outcome.en_US
dc.description.sponsorshipTrakya University Scientific Research Fund (TUBAP)en_US
dc.description.sponsorshipThis study was supported by the Trakya University Scientific Research Fund (TUBAP).en_US
dc.identifier.doi10.4103/0973-1482.203596
dc.identifier.endpage1078en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue5en_US
dc.identifier.pmid30197351en_US
dc.identifier.scopus2-s2.0-85053306813en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1075en_US
dc.identifier.urihttps://doi.org/10.4103/0973-1482.203596
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20288
dc.identifier.volume14en_US
dc.identifier.wosWOS:000444491800028en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCXCL12en_US
dc.subjectGeneticen_US
dc.subjectNon-Hodgkin Lymphomaen_US
dc.subjectRs18011157 Polymorphismen_US
dc.subjectBreast-Canceren_US
dc.subjectB-Cellsen_US
dc.subjectChemokineen_US
dc.subjectRisken_US
dc.subjectPathogenesisen_US
dc.titleCXCL12 rs18011157 polymorphism in patients with non-Hodgkin's lymphoma: Is it associated with poor outcome?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu